Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 2 | Mind Blowing Facts

Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing

The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.

International Business Times

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw…

The Economic Times

Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated steatohepatitis in adults. Poviztra contains innovator semaglutide manufactured in Europe by Novo Nordisk. The approval expands access to treatment for this progressive liver disease. This marks a significant milestone…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion…

The Economic Times

Once-a-week insulin launched in India, but doctors say it won't replace daily shots for all

India now offers Awiqli, a new once-weekly basal insulin for diabetes patients. This drug reduces annual injections from 365 to just 52 for many individuals. Experts suggest Awiqli is an additional option, not a complete replacement for daily insulin. It is best suited for patients who still produce some insulin…

The Economic Times

A Shot Every Two Weeks Instead of Weekly: New GLP-1 Drug Shows Strong Trial Results

A new biweekly GLP-1 drug called bofanglutide showed strong blood sugar and weight loss results in a Phase 2b trial. Monthly injectables and oral pills are also in the pipeline.

Novo Nordisk launches once-weekly basal insulin 'Awiqli' in India as diabetes rates increase

Novo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to daily injections for diabetes patients. Awiqli aims to reduce barriers to insulin initiation, which is often delayed in India. The Indian insulin market is projected to grow significantly in…

The Economic Times

inkl

Read news from The Economist, FT, and more,
with one subscription

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies

Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo Nordisk

The Guardian - UK

Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk, which makes Ozempic and Wegovy. NVO stock has been moving up, so is it overvalued now?

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay.

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay.

Popular Novo Nordisk and Eli Lilly drugs are included

The Independent UK

Everything you need to know about the new Wegovy pill – and whether you should take it or not

Everything you need to know about the new Wegovy pill – and whether you should take it or not

LET’S UNPACK THAT: With massive demand for the GLP-1 tablets as they are approved for use in the UK, Helen Coffey asks experts how they differ from the jab and whether they are the next big step in the weight-loss revolution

The Independent UK

Novo Nordisk reveals cyberattack: Ozempic and Wegovy maker says clinical trials data breached

Novo Nordisk reveals cyberattack: Ozempic and Wegovy maker says clinical trials data breached

The company says the data is pseudonymous and apparently can't be linked to actual people.

UK approves Novo weight-loss pill to edge open European market

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Economic Times

FDA issues new kidney warning for weight loss pill

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

From Crisis to Possible Cure Path: San Antonio Battles Highest Diabetes Rates as Wegovy and Medicare (United States) Expansion Offer New Hope

Diabetes care is entering a new era in San Antonio as the Wegovy pill and expanded Medicare coverage offer new hope for preventing and managing diabetes in one of America's hardest-hit cities.

5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

The Economic Times

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to market by as much as two-thirds. Its center in Bengaluru, India, is becoming crucial for global drug preparations.

Get all your
news in one place.

100's of premium titles.
One news app.

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings

SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company" or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), pending final resolution of the arbitration proceedings…

The Economic Times

CEOs are getting ruthless about worker performance

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volume growth, positive mix, consistent growth margin expansion." This shift towards "performance cultures" involves tougher accountability, potential layoffs, and a focus on tangible outcomes, signaling a departure from the more empathetic approach of the…

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

1 2 3 4 5

People

Mark Zuckerberg

Philipp Navratil

Fernando Fernandez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Court of Appeal

the Court of Appeal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,173 stories

148,541 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play